--- title: "From Radiology to Drug Discovery, Survey Reveals AI Is Delivering Clear Return on Investment in Healthcare" description: "AI is transforming healthcare, with a significant increase in adoption across various sectors. NVIDIA's survey reveals that 70% of organizations are using AI, with 85% reporting revenue growth and 80%" type: "news" locale: "en" url: "https://longbridge.com/en/news/276747407.md" published_at: "2026-02-24T14:07:28.000Z" --- # From Radiology to Drug Discovery, Survey Reveals AI Is Delivering Clear Return on Investment in Healthcare > AI is transforming healthcare, with a significant increase in adoption across various sectors. NVIDIA's survey reveals that 70% of organizations are using AI, with 85% reporting revenue growth and 80% cost reduction due to AI. Key applications include medical imaging and drug discovery, with a strong emphasis on open-source software. AI budgets are expected to rise, with 85% of respondents planning to increase spending. The focus is on integrating AI into existing workflows to enhance efficiency and patient care. AI is accelerating every aspect of healthcare — from radiology and drug discovery to medical device manufacturing and new treatment methods enabled by digital twins of the human body. NVIDIA’s second annual “State of AI in Healthcare and Life Sciences” survey report reveals how the industry is moving from AI experimentation to execution, reaping return on investment (ROI) on core applications like medical imaging and drug discovery. The industry is also embracing open source software and AI models to tackle specific use cases, as well as exploring using agentic AI to speed knowledge retrieval and research paper analysis. Highlights from this year’s report include: - 70% of respondents said their organizations are actively using AI, up from 63% in 2024. - 69% said they’re using generative AI and large language models, up from 54%. - 82% said open source software and models are moderately to extremely important to their organizations’ AI strategy. - 47% said they’re using or assessing agentic AI. - 85% of executives said AI is helping increase revenue, and 80% said it’s helping reduce costs. “Over the next 12-18 months, the most visible and scalable impact of AI will come from logistics and administrative streamlining,” said John Nosta, president of NostaLab, a healthcare think tank. “That’s where adoption curves are already steep — scheduling, documentation, coding, utilization management and care coordination.” Read more below on some of the report’s key findings. ## **AI Adoption Ramps Up Across Healthcare and Life Sciences** AI adoption is up across every industry segment in this year’s survey — spanning digital healthcare, pharmaceutical and biotechnology, payers and providers, and medical technology and tools — with digital healthcare leading at 78%, followed by medical technology at 74%. The top industry workload was generative AI and large language models, according to 69% of respondents. AI for data analytics and data science was the second most-used workload, followed by predictive analytics. New to the survey, agentic AI ranked fourth, with 47% of respondents saying they’re using or assessing AI agents. “Scaling generative AI in healthcare starts with focusing on real clinical and operational problems, rather than the technology itself,” said Dr. Annabelle Painter, clinical AI strategy lead at Visiba U.K. “The organizations seeing impact are those that embed AI into existing workflows instead of layering AI on top as a separate tool.” Healthcare and life sciences organizations are deploying these AI workloads across a variety of use cases, each specific to their primary functions. For example, 61% of respondents from medical technology said they’re using AI for medical imaging, such as radiologists using it to work more quickly and efficiently, while 57% from pharmaceutical and biotechnology said drug discovery is being driven by AI. For the entire industry, the top AI use cases were clinical decision support (such as radiologists highlighting areas of concern on a scan), medical imaging and workflow optimization. ## **AI Budgets to Increase With Strong ROI** AI is helping healthcare and life sciences organizations become even better at their core competencies — underscoring strong ROI. In addition to increasing annual revenue and reducing annual costs, AI is boosting back-office productivity through workflow optimization and is scaling across other key business operations such as patient interaction and administrative tasks. For example, 57% of respondents from the medical technology segment reported seeing ROI from deploying AI for medical imaging. Nearly half (46%) of pharmaceutical and biotechnology respondents said AI for drug discovery and development was among their top ROI use cases. The top ROI use case for digital healthcare providers was virtual health assistants and chatbots, according to 37%, while 39% of respondents from payers and providers (which include hospitals, primary care providers and insurance companies) cited administrative tasks and workflow optimization as their top area of ROI. As a result of AI’s positive impact, 85% of respondents said their AI budgets would increase this year, with another 12% saying budgets would stay the same. For almost half of respondents (46%), AI spending will increase significantly, by more than 10%. “Healthcare organizations that successfully integrate AI are those that explicitly fund and prioritize evaluation as a core operational function, ensuring AI delivers measurable improvements in safety, quality and patient care over time,” said Painter. ## **Using Open Source for Domain-Specific AI Deployment** Leaning into open source models and software allows enterprises to build domain-specific applications, lending them greater flexibility and efficiency while boosting business returns. The healthcare industry has embraced open source, with 82% of survey respondents stating it’s moderately to extremely important to their AI strategy. “Open models will shape the intellectual field,” said Nosta. “They are essential for exploration and for keeping the field honest. But in clinical environments where safety, liability and accountability are nonnegotiable, proprietary systems will remain necessary for validation, integration and trust. The key insight here is that discovery will be open, and deployment will demand stewardship.” Download the “State of AI in Healthcare and Life Sciences: 2026 Trends” report for in-depth results and insights. *Sign up for* *NVIDIA’s healthcare and life sciences newsletter**.* ### Related Stocks - [NVDA.US - NVIDIA](https://longbridge.com/en/quote/NVDA.US.md) - [NVDX.US - T-Rex 2X Long NVIDIA Daily Target ETF](https://longbridge.com/en/quote/NVDX.US.md) - [NVDU.US - Direxion Daily NVDA Bull 2X Shares](https://longbridge.com/en/quote/NVDU.US.md) - [NVDL.US - GraniteShares 2x Long NVDA Daily ETF](https://longbridge.com/en/quote/NVDL.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 存储 vs GPU | 过去六个月的业绩表现：SK 海力士 +300%，三星电子 +180%，英伟达 +8%。 而英伟达财报会改变这一局面吗？ | [Link](https://longbridge.com/en/news/276799944.md) | | 新电信数码基础设施公司与英伟达合作 设应用人工智能中心 \| 联合早报网 | 新加坡电信旗下的数码基础设施公司与英伟达合作，设立应用人工智能卓越中心，预计三个月后在榜鹅数码园区投入运营。该中心将帮助企业在实际运营环境中验证 AI 模型和工作流程，整合 AI 基础设施和全球技术资源，缩短从试点到规模化的周期。CEO 张 | [Link](https://longbridge.com/en/news/276722866.md) | | Corcept 医疗｜8-K：2025 财年营收 7.61 亿美元不及预期 | | [Link](https://longbridge.com/en/news/276787344.md) | | Quadria Capital 以 6.17 亿元完成收购 Apex Healthcare \| 联合早报网 | Quadria Capital 率领的财团以约 19 亿令吉（6 亿 1700 万新元）完成对马来西亚制药公司 Apex Healthcare 的收购，并将其私有化。这是马来西亚医疗保健领域最大规模的私有化交易，也是东南亚五年来同类交易中最 | [Link](https://longbridge.com/en/news/276699225.md) | | 太空制药–商业航天的 “新场景” | 大摩表示，可复用火箭让发射成本暴降 10 倍，医药行业或将率先跑通商业闭环。微重力环境下药物晶体纯度更高、缺陷更少，胰岛素晶体体积可达地球 34 倍。行业先行者 Varda 已完成 HIV 药物太空结晶回收，目前融资 3.28 亿美元，目标 | [Link](https://longbridge.com/en/news/276549524.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.